Servier entered a multiyear research and development collaboration with Insilico Medicine to leverage the Pharma.AI platform for oncology target discovery and early development. Insilico will receive up‑front and near‑term payments (reported up to ~$32 million in one disclosure) and the partners will work to identify and advance challenging cancer targets using AI‑driven workflows. The agreements underline continued pharma investment in computational discovery engines to accelerate early R&D and de‑risk discovery for difficult oncology targets.